DK2040745T3 - Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger - Google Patents

Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger

Info

Publication number
DK2040745T3
DK2040745T3 DK07764444.1T DK07764444T DK2040745T3 DK 2040745 T3 DK2040745 T3 DK 2040745T3 DK 07764444 T DK07764444 T DK 07764444T DK 2040745 T3 DK2040745 T3 DK 2040745T3
Authority
DK
Denmark
Prior art keywords
vaccination
expansion
protein fragments
cell repertoire
peptide mixtures
Prior art date
Application number
DK07764444.1T
Other languages
Danish (da)
English (en)
Inventor
Claus Aagaard
Peter Andersen
Jes Dietrich
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of DK2040745T3 publication Critical patent/DK2040745T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07764444.1T 2006-06-28 2007-06-26 Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger DK2040745T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600861 2006-06-28
PCT/DK2007/000312 WO2008000261A2 (en) 2006-06-28 2007-06-26 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Publications (1)

Publication Number Publication Date
DK2040745T3 true DK2040745T3 (da) 2013-03-18

Family

ID=38845996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764444.1T DK2040745T3 (da) 2006-06-28 2007-06-26 Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger

Country Status (11)

Country Link
US (2) US8105614B2 (enExample)
EP (3) EP2402023A1 (enExample)
JP (1) JP5165681B2 (enExample)
KR (1) KR20090024292A (enExample)
AU (1) AU2007264205B2 (enExample)
BR (1) BRPI0713978A2 (enExample)
CA (1) CA2654271A1 (enExample)
DK (1) DK2040745T3 (enExample)
ES (1) ES2400531T3 (enExample)
RU (1) RU2490024C2 (enExample)
WO (1) WO2008000261A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941545D1 (de) 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
MX2009013008A (es) * 2007-05-31 2010-06-09 Vacunas para la influenza.
BRPI0811796A2 (pt) * 2007-06-26 2020-04-28 Statens Serum Institut Uso de um monomicolil glicerol (mmg) ou de homólogos ou análogos sintéticos e versões modificadas, adjuvante ou imunomodulador, homólogo ou análogo de mmg sintético ou uma versão modificada, vacina e sistema de aplicação
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
TR201903223T4 (tr) * 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
US20110104195A1 (en) * 2009-11-05 2011-05-05 Joao Aguiar Plasmodium falciparum sporozoite and liver stage antigens
US9107875B2 (en) * 2009-11-18 2015-08-18 Auburn University Low antigen-dose immunization for maximizing T-helper cell 1 (Th1) immunity against a pathogen
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
DK3079716T3 (da) * 2013-12-13 2019-08-19 Us Health Multiepitop-tarp-peptidvaccine og anvendelser deraf.
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN117064854A (zh) * 2023-08-14 2023-11-17 广州谦毅生物医药有限公司 一种卡瓦脂质体的制备技术

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
EP0979867A3 (en) * 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
CZ302870B6 (cs) * 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2006002642A2 (en) 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
FR2873467A1 (fr) 2004-07-26 2006-01-27 Proton World Internatinal Nv Enregistrement d'une cle dans un circuit integre
DK1991266T3 (da) * 2006-01-26 2013-08-26 Zoetis P Llc Nye glycolipid-adjuvant-sammensætninger
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides

Also Published As

Publication number Publication date
EP2402024A1 (en) 2012-01-04
EP2040745A2 (en) 2009-04-01
RU2009102389A (ru) 2010-08-10
RU2490024C2 (ru) 2013-08-20
AU2007264205A1 (en) 2008-01-03
US8105614B2 (en) 2012-01-31
ES2400531T3 (es) 2013-04-10
JP2009541373A (ja) 2009-11-26
JP5165681B2 (ja) 2013-03-21
EP2040745B1 (en) 2012-12-05
US20120156282A1 (en) 2012-06-21
KR20090024292A (ko) 2009-03-06
AU2007264205B2 (en) 2013-04-18
US20080008724A1 (en) 2008-01-10
WO2008000261A2 (en) 2008-01-03
EP2402023A1 (en) 2012-01-04
BRPI0713978A2 (pt) 2012-11-27
CA2654271A1 (en) 2008-01-03
WO2008000261A3 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
DK2040745T3 (da) Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
DK2594588T3 (da) Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM-ikke-Ig-protein-scaffold til anvendelse i terapi
DK2370465T3 (da) Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4
BR112013029892A2 (pt) polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
DK2150275T3 (da) Ande-embryoniske afledte stamcellelinjer til fremstillingen af virale vacciner
CR20140169A (es) Proteinas de union al antigeno cd27l
BR112014000264A2 (pt) métodos para aumentar e para diminuir uma função efetora de um polipeptídeo parental e de um anticorpo parental, para aumentar uma função efetora de uma combinação de pelo menos um primeiro e um segundo polipeptídeo parental, para induzir uma resposta efetora contra uma célula, membrana celular, ou vírion, para aumentar a especificidade de uma combinação de pelo menos um primeiro e um segundo polipeptídeo parental, variante de um polipeptídeo parental, composição, e, kit de partes
DK2061803T4 (da) Fremgangsmåde til oprensning af fc-holdige proteiner
DK2155838T3 (da) Fremgangsmåde til fremstilling af forgrenede carbonhydrider
DK2054428T3 (da) Udvikling af bestanddele til denque-virus-vaccine
CL2007003807A1 (es) Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado
BRPI0817079A2 (pt) processos para fabricação recombinante de anticorpos anti-rsv
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BR112012004221A2 (pt) "anticorpos, composição farmacêutica, uso do anticorpo, ácido nucleico, vetores de expressão, célula hospedeira procariótica e método para a produção de um anticorpo humanizado recombinante"
DK3290404T3 (da) 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrilderivater som intermediater til fremstillingen af [(5-(halophenyl)-3-hydroxypyridin-2-carbonyl)-amino]alkansyrederivater
DK2193142T3 (da) Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
DK2220021T3 (da) Fremgangsmåde til fremstilling af terephtalsyre
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
CR10523A (es) Cepa bg1 de thermoanaerobacter mathranii
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
CL2008001129A1 (es) Variente de asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos; vector y celula huesped; metodo para producir asparraginasa; composicion que comprende la variante; uso de la variante de asparraginasa; proceso